Liver Cancer

Enrollment in pivotal phase 3 study of primary liver cancer drug completed

Published in Cancer Weekly, May 17th, 2005

Eximias Pharmaceutical Corporation (Eximias) announced that it has completed enrollment in its pivotal phase 3 clinical study with Thymitaq in patients with inoperable primary liver cancer (hepatoma, hepatocellular carcinoma or HCC).

The phase 3 study, coined the ETHECC trial (Evaluation of Thymitaq in Unresectable Hepatocellular Carcinoma), is comparing survival in a randomized trial of patients with inoperable primary liver cancer treated with Thymitaq, an investigational product, to patients treated with doxorubicin.

There is no treatment approved by the United States Food and Drug Administration (FDA) or the European Agency for the Evaluation of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry